ArticleFrontiers in pharmacology2025

Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials.

Peng Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.